Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.

Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE.

Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6. Epub 2006 Feb 10.

2.

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Sharma SK, Sharma A, Kadhiravan T, Tharyan P.

Cochrane Database Syst Rev. 2013 Jul 5;(7):CD007545. doi: 10.1002/14651858.CD007545.pub2. Review.

PMID:
23828580
3.
4.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.

5.

Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21.

6.

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101. Epub 2006 Mar 30.

7.

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.

Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH.

Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61. doi: 10.1164/rccm.201012-1949OC. Epub 2011 Feb 17.

9.

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Sharma SK, Sharma A, Kadhiravan T, Tharyan P.

Evid Based Child Health. 2014 Mar;9(1):169-294. doi: 10.1002/ebch.1962.

PMID:
25404581
10.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.

11.

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.

McClintock AH, Eastment M, McKinney CM, Pitney CL, Narita M, Park DR, Dhanireddy S, Molnar A.

BMC Infect Dis. 2017 Feb 14;17(1):146. doi: 10.1186/s12879-017-2245-8.

12.
13.

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.

Tam CM, Chan SL, Lam CW, Leung CC, Kam KM, Morris JS, Mitchison DA.

Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1726-33.

PMID:
9620898
14.

Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team.

Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7.

15.

Treatment of latent tuberculosis infection.

Parekh MJ, Schluger NW.

Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20. Review.

PMID:
24056289
16.

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.

17.

Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.

Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.

18.

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.

Tam CM, Chan SL, Kam KM, Goodall RL, Mitchison DA.

Int J Tuberc Lung Dis. 2002 Jan;6(1):3-10.

PMID:
11931398
19.

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team.

N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210.

20.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.

Ann Intern Med. 2002 Oct 15;137(8):640-7.

PMID:
12379063

Supplemental Content

Support Center